Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above 200-Day Moving Average – What’s Next?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.59 and traded as high as $8.06. Cumberland Pharmaceuticals shares last traded at $7.85, with a volume of 137,133 shares changing hands.

Analyst Ratings Changes

A number of analysts recently weighed in on CPIX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen downgraded shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cumberland Pharmaceuticals presently has an average rating of “Sell”.

Cumberland Pharmaceuticals Trading Up 7.5%

The stock has a market cap of $117.59 million, a PE ratio of -16.02 and a beta of 0.09. The company has a current ratio of 0.95, a quick ratio of 0.79 and a debt-to-equity ratio of 0.25. The firm has a fifty day simple moving average of $6.05 and a two-hundred day simple moving average of $4.59.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $9.13 million for the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%.

Cumberland Pharmaceuticals Dividend Announcement

The business also recently declared a dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, July 23rd will be issued a $1.50 dividend.

Institutional Trading of Cumberland Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in shares of Cumberland Pharmaceuticals during the 2nd quarter worth $34,000. Arrowstreet Capital Limited Partnership bought a new position in Cumberland Pharmaceuticals in the first quarter valued at $66,000. Two Sigma Investments LP increased its stake in Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,326 shares during the last quarter. Marshall Wace LLP purchased a new stake in Cumberland Pharmaceuticals during the fourth quarter valued at about $192,000. Finally, Geode Capital Management LLC raised its position in Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after purchasing an additional 5,653 shares in the last quarter. 15.51% of the stock is owned by institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.